Intracerebroventricular injection of propionic acid, an enteric metabolite implicated in autism, induces social abnormalities that do not differ between seizure-prone (FAST) and seizure-resistant (SLOW) rats

Behavioural Brain Research

Volumn 278, Issue , 2015, Pages 542-548

  Shultz, Sandy R ^a   Aziz, Noor A B ^a   Yang, Li ^a,b   Sun, Mujun ^a   MacFabe, Derrick F ^c   O'Brien, Terence J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b KUNMING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Animal model; Astrogliosis; Attention deficit hyperactivity disorder; Autism; Short chain fatty acid

Indexed keywords

PROPIONIC ACID; GLIAL FIBRILLARY ACIDIC PROTEIN; PROPIONIC ACID DERIVATIVE;

ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; AUTISM; BEHAVIOR DISORDER; BRAIN CORTEX; CONTROLLED STUDY; CORPUS CALLOSUM; DISEASE PREDISPOSITION; IMMUNOFLUORESCENCE; LOCOMOTION; MALE; NONHUMAN; OPEN FIELD TEST; RAT; SEIZURE; SOCIAL BEHAVIOR; TASK PERFORMANCE; ANALYSIS OF VARIANCE; ANIMAL; ANTISOCIAL PERSONALITY DISORDER; ASTROCYTE; CHEMICALLY INDUCED; DRUG EFFECTS; EXPLORATORY BEHAVIOR; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; PATHOPHYSIOLOGY;

ANALYSIS OF VARIANCE; ANIMALS; ASTROCYTES; CEREBRAL CORTEX; CORPUS CALLOSUM; EXPLORATORY BEHAVIOR; GLIAL FIBRILLARY ACIDIC PROTEIN; INJECTIONS, INTRAVENTRICULAR; LOCOMOTION; MALE; PROPIONATES; RATS; SEIZURES; SOCIAL BEHAVIOR DISORDERS;

EID: 84911435106     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.10.050     Document Type: Article

References (50)

1. Baio J. Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ 2012, 61:1-19.
2. Jeste S.S., Geschwind D.H. Disentangling the heterogeneity of autism spectrum disorders through genetic findings. Nat Rev Neurol 2014, 10:74-81.
3. Rossignol D.A., Genuis S.J., Frye R.E. Environmental toxicants and autism spectrum disorders: a systemic review. Transl Psychiatry 2014, 4:e360.
4. Reiersen A.M., Todd A.D. Co-occurrence of ADHD and autism spectrum disorders: phenomenology and treatment. Expert Rev Neurother 2008, 8:657-669.
5. Frye R.E., Melnyk S., MacFabe D.F. Unique acyl-carnitine profiles are potential biomarkers for acquired mitochondrial disease in autism spectrum disorder. Transl Psychiatry 2013, 3:e220.
6. Herbert M.R. Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders. Curr Opin Neurol 2010, 23:103-110.
7. MacFabe D. Autism: metabolism, mitochondria, and microbiome. Glob Adv Health Med 2013, 2:52-66.
8. Wang L., Conion M.A., Christophersen C.T., Sorich M.J., Angley M.T. Gastrointestinal microbiota and metabolite biomarkers in children with autism spectrum disorders. Biomark Med 2014, 8:331-344.
9. MacFabe D. Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders. Microb Ecol Health Dis 2012, 23:19260.
10. MacFabe D.F., Cain D.P., Rodriguez-Capote K., Franklin A.E., Hoffman J.E., Boon F., Taylor A.R., Kavaliers M., Ossenkopp K.P. Neurobiological effects of intraventricular propionic acid in rats: possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders. Behav Brain Res 2007, 176:149-169.
11. Shultz S.R., MacFabe D.F. Propionic acid model of autism. Comprehensive Guide to Autism 2014, 1755-1778. Springer. V.B. Patel, V.R. Preedy, C.R. Martin (Eds.).
12. Shultz S.R., MacFabe D.F., Ossenkopp K.P., Scratch S., Whelan J., Taylor R., Cain D.P. Intracerebroventricular injection of propionic acid, an enteric bacterial metabolic end-product, impairs social behavior in the rat: implications for an animal model of autism. Neuropharmacology 2008, 54:901-911.
13. Shultz S.R., MacFabe D.F., Martin S., Jackson J., Taylor R., Boon F., Ossenkopp K.P., Cain D.P. Intracerebroventricular injection of the enteric bacterial metabolic product propionic acid impair cognition and sensorimotor ability in the Long-Evans rat: further development of a rodent model of autism. Behav Brain Res 2009, 200:33-41.
14. MacFabe D.F., Cain N.E., Boon F., Ossenkopp K.P., Cain D.P. Effects of the enteric bacterial metabolic product propionic acid on object-directed behavior, social behavior, cognition, and neuroinflammation in adolescent rats: relevance to autism spectrum disorder. Behav Brain Res 2011, 217:47-54.
15. Thomas R.H., Foley K.A., Mepham J.R., Tichenoff L.J., Possmayer MacFabe D.F. Altered brain phospholipid and acylcarnitine profiles in propionic acid infused rodents: further development of a potential model of autism spectrum disorders. J Neurochem 2010, 113:515-529.
16. Thomas R.H., Meeking M.M., Mepham J.R., Tichenoff L., Possmayer F., Liu S., MacFabe D.F. The enteric bacterial metabolite propionic acid alters brain and plasma phospholipid molecular species: further development of a rodent model of autism spectrum disorders. J Neuroinflammation 2012, 9:153.
17. Gilby K.L., O'Brien T.J. Epilepsy autism, and neurodevelopment: kindling a shared vulnerability?. Epilepsy Behav 2013, 26:370-374.
18. Racine R.J., Steingart M., McIntyre D.C. Development of kindling-prone and kindling-resistant rats: selective breeding and electrophysiology studies. Epilepsy Res 1999, 35:183-195.
19. Argyropoulos A., Gilby K.L., Hill-Yardin E.L. Studying autism in rodent models: reconciling endophenotypes with comorbidities. Front Hum Neurosci 2013, 7:417.
20. Gilby K.L. A new rat model for vulnerability to epilepsy and autism spectrum disorders. Epilepsia 2008, 49:108-110.
21. Shultz S.R., Cardamone L., Liu Y.R., Hogan R.E., Maccotta L., Wright D.K., Zheng P., Koe A., Gregoire M.C., Williams J.P., Hicks R.J., Jones N.C., Myers D.E., O'Brien T.J., Bouilleret V. Can structural or functional changes following traumatic brain injury in the rat predict epileptic outcome?. Epilepsia 2013, 54:1240-1250.
22. Prut L., Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 2003, 463:3-33.
23. Jones N.C., Cardamone L., Williams J.P., Salzberg M.R., Myers D., O'Brien T.J. Experimental traumatic brain injury induces a pervasive hyperanxious phenotype in rats. J Neurotrauma 2008, 25:1367-1374.
24. Shultz S.R., Tan X.L., Wright D.K., Liu S.J., Semple B.D., Johnston L., Jones N.C., Cook A.D., Hamilton J.A., O'Brien T.J. Granulocyte-macrophage colony-stimulating factor is neuroprotective in experimental brain injury. J Neurotrauma 2014, 31:976-983.
25. Shultz S.R., Bao F., Weaver L.C., Cain D.P., Brown A. Treatment with an anti-CD11d integrin antibody reduces neuroinflammation and improves outcome in a rat model of repeated concussion. J Neuroinflammation 2013, 10:26.
26. Edmonson C., Ziats M.N., Rennert O.M. Altered glial marker expression in autistic post-mortem prefrontal cortex and cerebellum. Mol Autism 2014, 5:3.
27. Vargas D.L., Nascimbene C., Krishnan C., Zimmerman A.W., Pardo C.A. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005, 57:67-81.
28. Zeidan-Chulia F., Salmina A.B., Malinovskaya N.A., Noda M., Verkhratsky A., Moreira J.C. The glial perspective of autism spectrum disorders. Neurosci Biobehav Rev 2014, 38:160-172.
29. Bonnet U., Bingmann D., Wiemann M. Intracellular pH modulate spontaneous and epileptiform bioelectric cell coupling of hippocampal CA3-neurones. Eur Neuropsychopharmacol 2000, 10:97-103.
30. + accumulation in rat hypothalamic synaptosomes: involvement of calcium ions. Neurochem Int 2003, 43:9-17.
31. Karuri A.R., Dobrowsky E., Tannock I.F. Selective cellular acidification and toxicity of weak organic acids in an acidic microenvironment. Br J Cancer 1993, 68:1080-1087.
32. Mitsui R., Ono S., Karaki S., Kuwahara A. Neural and non-neural mediation of propionate-induced contractile responses in rat distal colon. Neurogastroenterol Motil 2005, 17:585-594.
33. Severson C.A., Wang W., Pieribone V.A., Dohle C.I., Richerson G.B. Midbrain serotonergic receptors neurons are central pH chemoreceptors. Nat Neurosci 2003, 6:1139-1140.
34. Al-Lahham S.H., Peppelenbosch M.P., Roelofsen H., Vonk R.J., Venema K. Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms. Biochim Biophys Acta 2010, 1801:1175-1183.
35. Reinhart C.J., Pellis S.M., McIntyre D.C. Development of play fighting in kindling-prone (FAST) and kindling-resistant (SLOW) rats: how does the retention of phenotypic juvenility affect the complexity of play?. Dev Psychobiol 2004, 45:83-92.
36. Reinhart C.J., McIntyre D.C., Metz G.A., Pellis S.M. Play fighting between kindling-prone (FAST) and kindling-resistant (SLOW) rats. J Comp Psychol 2006, 120:19-30.
37. Azarbar A., McIntyre D.C., Gilby K.L. Caloric restriction alters seizure disposition and behavioral profiles in seizure-prone (fast) versus seizure-resistant (slow) rats. Behav Neurosci 2010, 124:106-114.
38. Gilby K.L., Jans J., McIntyre D.C. Chronic omega-3 supplementation in seizure-prone versus seizure resistant rat strains: a cautionary tale. Neuroscience 2009, 163:750-758.
39. McIntyre D.C., Gilby K.L. Genetically seizure-prone or seizure-resistant phenotypes and their associated behavioral comorbidities. Epilepsia 2007, 48:30-32.
40. Hamoda H.M., Guild D.J., Gumlak S., Travers B.H., Gonzalez-Heydrich J. Association between attention-deficit/hyperactivity disorder and epilepsy in pediatric populations. Expert Rev Neurother 2009, 9:1747-1754.
41. Russell V.A., Oades R.D., Tannock R., Killeen P.R., Auerbach J.G., Johansen E.B., Sagvolden T. Response variability in attention-deficit/hyperactivity disorder: a neuronal and glial energetics hypothesis. Behav Brain Funct 2006, 2:30.
42. Strickland A.D. Prevention of cerebral palsy, autism spectrum disorder, and attention deficit-hyperactivity disorder. Med Hypotheses 2014, 82:522-528.
43. Choi J., Nordli D.R., Alden T.D., DiParti A., Laux L., Kelley K., Rosenow J., Schuele S.U., Rajaram V., Koh S. Cellular injury and neuroinflammation in children with chronic intractable epilepsy. J Neuroinflammation 2009, 6:30.
44. Crunelli V., Carmignoto G., Steinhauser C. Astrocytic targets provide new avenues for the therapeutic treatment of epilepsy. Neuroscientist 2014, epub ahead of print.
45. Pardo C.A., Nabbout R., Galanopoulou A.S. Mechanisms of epileptogenesis in pediatric epileptic syndromes: Rasmussen encephalitis, infantile spasms, and febrile infection-related epilepsy syndrome (FIRES). Neurotherapeutics 2014, 11:297-310.
46. Pekny M., Wilhelmsson U., Pekna M. The dual role of astrocyte activation and reactive gliosis. Neurosci Lett 2014, 565:30-38.
47. Vitaliti G., Pavone P., Mahmood F., Nunnari G., Falsaperla R. Targeting inflammation as a therapeutic strategy for drug-resistant epilepsies: An update of new immune-modulating approaches. Hum Vaccin Immunother 2014, 10:868-875.
48. Foley K.A., Ossenkopp K.P., Kavaliers M., MacFabe D.F. Pre- and neonatal exposure to lipopolysaccharide or the enteric metabolite, propionic acid, alters development and behavior in adolescent rats in a sexually dimorphic manner. PLoS One 2014, 9(1):e87072. 10.1371/journal.pone.0087072. eCollection 2014.
49. Foley K.A., MacFabe D.F., Kavaliers M., Osssenkopp K.P. Sexually dimorphic effects of prenatal exposure to lipopolysaccharide, and prenatal and postnatal exposure to propionic acid, on acoustic startle response and prepulse inhibition in adolescent rats: relevance to autism spectrum disorders. Behav Brain Res 2014, epub ahead of print.
50. Foley K.A., MacFabe D.F., Vaz A., Ossenkopp K.P., Kavaliers M. Sexually dimorphic effects of prenatal exposure to propionic acid and lipopolysaccharide on social behavior in neonatal, adolescent, and adult rats: implications for autism spectrum disorders. Int J Dev Neurosci 2014, 39:68-78.